Study summary

An actinium-225 radioligand met its goal after lutetium therapy

ACTION-1 trial · 343 people, phase 3 · Topline October 2026 (interim analysis)

What was tested

RYZ101, an alpha-emitting actinium-225 radioligand, against standard treatment for somatostatin-receptor-positive GEP-NETs that grew after lutetium-177 therapy.

What they found

The trial met its main goal of longer time before growth; figures were not yet released.

What it means

Could become the first option after lutetium radioligand therapy stops working.

BioPharm International ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.